相关实验视频
Updated: Jul 28, 2025

05:21
Establishment of A Mouse Model of Aqueous Deficiency Dry Eye
Published on: November 1, 2024
663
干眼病:对抗炎症疗法的综述
Annie Nguyen1,2, Ajay Kolluru1, Talia Beglarian1
1Keck School of Medicine of University of Southern California, USA.
Taiwan journal of ophthalmology
|May 30, 2023
概括
干眼病 (DED) 是一种常见的疾病,影响视力和生活质量. 这次审查涵盖了DED.
科学领域:
- 眼科医生 眼科 眼科
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 干眼病 (DED) 是一种常见的慢性眼部疾病.
- DED显著损害视觉功能,舒适度和日常生活.
- 角膜和结膜的炎症是DED病原体的核心.
研究的目的:
- 审查DED的患病率和炎症病理生理学.
- 讨论目前针对DED的抗炎治疗策略.
主要方法:
- 关于DED患病率和病理生理学的文献综述.
- 对DED的抗炎治疗方法的分析.
主要成果:
- DED是多因素的,炎症是主要的驱动因素.
- 不同的抗炎疗法在DED管理中表现出不同的有效性.
结论:
- 了解DED的炎症基础对于有效治疗至关重要.
- 存在一系列的抗炎选择,需要量身定制的方法.
相关概念视频
Open Angle Glaucoma: Treatment
497
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
497
Inflammatory Bowel Disease IV: Pharmacological Management
159
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
159
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
161
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
161
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
205
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
205
Angle Closure Glaucoma: Treatment
584
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
584
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
178
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
178

